Tamoxifen

Generic Name
Tamoxifen
Brand Names
Soltamox
Drug Type
Small Molecule
Chemical Formula
C26H29NO
CAS Number
10540-29-1
Unique Ingredient Identifier
094ZI81Y45
Background

Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...

Indication

Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.

Associated Conditions
Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
Associated Therapies
Ovulation induction therapy
Clinical Trials
Related News

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

First Posted Date
2023-12-21
Last Posted Date
2024-08-07
Lead Sponsor
University of Washington
Target Recruit Count
60
Registration Number
NCT06179303
Locations
🇺🇸

Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

First Posted Date
2023-10-10
Last Posted Date
2024-10-08
Lead Sponsor
QuantumLeap Healthcare Collaborative
Target Recruit Count
400
Registration Number
NCT06075953
Locations
🇺🇸

Berkeley Outpatient Center, Berkeley, California, United States

🇺🇸

UCSF, San Francisco, California, United States

🇺🇸

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

and more 5 locations

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

First Posted Date
2023-08-21
Last Posted Date
2024-11-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
90
Registration Number
NCT06001762
Locations
🇺🇸

Stamford Hospital, Stamford, Connecticut, United States

🇺🇸

Eastern Maine Medical Center (Northern Light), Brewer, Maine, United States

🇺🇸

New England Cancer Specialists, Scarborough, Maine, United States

and more 9 locations

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

First Posted Date
2023-07-19
Last Posted Date
2024-12-10
Lead Sponsor
AstraZeneca
Target Recruit Count
5500
Registration Number
NCT05952557
Locations
🇬🇧

Research Site, Whitchurch, United Kingdom

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

First Posted Date
2023-07-12
Last Posted Date
2024-04-15
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
80
Registration Number
NCT05941520
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

University of Kansas Cancer Center, Kansas City, Kansas, United States

and more 1 locations

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

First Posted Date
2023-06-06
Last Posted Date
2024-02-08
Lead Sponsor
Fudan University
Target Recruit Count
766
Registration Number
NCT05891093
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China

🇨🇳

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China

🇨🇳

Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 12 locations

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

First Posted Date
2023-04-06
Last Posted Date
2023-05-18
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
700
Registration Number
NCT05801705
Locations
🇨🇳

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

First Posted Date
2023-03-20
Last Posted Date
2024-11-06
Lead Sponsor
AstraZeneca
Target Recruit Count
4300
Registration Number
NCT05774951
Locations
🇻🇳

Research Site, Hue, Vietnam

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

First Posted Date
2022-12-21
Last Posted Date
2024-10-02
Lead Sponsor
MedSIR
Target Recruit Count
92
Registration Number
NCT05659563
Locations
🇫🇷

Hopital Europeen Georges Pompidou, Paris, France

🇪🇸

Institut Català d' Oncologia Badalona, Badalona, Barcelona, Spain

🇪🇸

Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain

and more 16 locations

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

First Posted Date
2022-12-09
Last Posted Date
2024-12-17
Lead Sponsor
Tolmar Inc.
Target Recruit Count
250
Registration Number
NCT05645536
Locations
🇧🇷

Centro Regional Integrado de Oncologia, Fortaleza, Ceara, Brazil

🇺🇸

Marin Cancer Care, Inc., Greenbrae, California, United States

🇺🇸

Holy Cross Hospital, Fort Lauderdale, Florida, United States

and more 17 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy